The efficacy of using modern antiseptic drugs in ointment form in the treatment of pyoderma and secondarily infected dermatoses

Abstract

BACKGROUND: Pyoderma is one of the most common diseases of the skin and its derivatives. Traditionally, topical antibacterial drugs are used as first-line drugs, but the growth of antibiotic resistance limits their use, and therefore the search for new promising forms of antiseptic drugs remains an urgent task. An antiseptic agent must have a wide antimicrobial spectrum, not irritate the skin and mucous membranes, and remain active for a long time; the antiseptic benzyldimethyl-myristoylamino-propylammonium ointment meets all these requirements.

AIM: to evaluate the efficacy and safety of 0.5% benzyldimethyl-myristoylamino-propylammonium ointment in the treatment of pyoderma and secondarily infected dermatoses.

MATERIALS AND METHODS: We followed 36 patients with identified polyresistance to topical antibacterial drugs aged 18 to 63 year. 1st group consisted of 22 patients with clinical forms of superficial pyoderma: superficial folliculitis ― 8 (36.4%) cases, sycosis vulgaris ― 4 (18.2%), impetigo vulgaris ― 4 (18.2%), dry streptoderma ― 3 (13.6%), paronychia ― 3 (13.6%). The 2nd cohort included 14 human test subjects with secondarily infected dermatosis: nummular eczema ― 6 cases (42.8%), atopic dermatitis ― 5 (35.8%), secondarily infected contact allergic dermatitis ― 3 (21.4%).

RESULTS: As a result of monotherapy with 0.5% benzyldimethyl-myristoylamino-propylammonium ointment in the pyoderma group, clinical recovery (with DIDS=0) was observed in 91.7% of the subjects. The most common dermoscopic pattern was a necrotic rod, the final one was a light red background. Comprehensive treatment of secondarily infected dermatosis in patients of group II, a clinical cure was stated in 71.4% of cases, which is associated with the predominance of chronic, recurrent dermatoses in this cohort of the study, it was noted that dermatosis has a moderate effect on their lives. Initially, during dermatoscopy, there were signs of an acute stage of examination (yellow scales/crusts, punctate vessels, hemorrhages), after therapy ― a stationary stage (white scales).

CONCLUSION: Miramistin ointment 0.5% has demonstrated high tolerability and efficacy against various forms of superficial pyoderma and secondarily infected dermatosis and can be recommended for effective use in clinical practice.

Keywords

pyoderma / eczema / antibiotic resistance / local therapy / antiseptics

References

[1] Butov YS. Dermatovenereology. National leadership. Brief edition. Ed. by Yu.S. Butova, Yu.K. Skripkina, O.L. Ivanova. Moscow: GEOTAR-Media; 2020. 896 p. (In Russ).

[2] Бутов Ю.С. Дерматовенерология. Национальное руководство. Краткое издание / под ред. Ю.С. Бутова, Ю.К. Скрипкина, О.Л. Иванова. Москва: ГЭОТАР-Медиа, 2020. 896 с.

[3] Kruglova LS, Yakovlev AB, Sten’ko AG, Talybova AM. Systemic antibiotic therapy: The efficacy of in the treatment of various clinical forms of pyoderma. Clin Dermatol Venereol. 2017;16(6):62–68. (In Russ). doi: 10.17116/klinderma201716662-68

[4] Круглова Л.С., Яковлев А.Б., Стенько А.Г., Талыбова А.М. Системная антибиотикотерапия: эффективность в лечении различных клинических форм пиодермий // Клиническая дерматология и венерология. 2017. Т. 16, № 6. С. 62–68.

[5] Tamrazova OB, Shmeleva EA, Mironova AK, Dubovets NF. Current views on etiopathogenesis, clinical manifestations and treatment of pyodermas in children. Med Advice. 2020;(1):118–129. (In Russ). doi: 10.21518/2079-701X-2020-1-118-129

[6] Тамразова О.Б., Шмелева Е.А., Миронова А.К., Дубовец Н.Ф. Cовременный взгляд на этиопатогенез, клинические проявления и лечение пиодермий у детей // Медицинский совет. 2020. № 1. С. 118–129. doi: 10.21518/2079-701X-2020-1-118-129

[7] Tamrazova OB. Silver-containing drugs in treatment of pyoderma. Clin Dermatol Venereol. 2014;12(3):49–57. (In Russ).

[8] Тамразова О.Б. Препараты серебра в лечение пиодермий // Клиническая дерматология и венерология. 2014. Т. 12, № 3. С. 49–57.

[9] Galli L, Venturini E, Bassi A, et al. Common community-acquired bacterial skin and softtissue infections in children: An intersociety consensus on impetigo, abscess, and cellulitis treatment. Clin Ther. 2019;41(3):532–551.e17. doi: 10.1016/j.clinthera.2019.01.010

[10] Galli L., Venturini E., Bassi A., et al. Common community-acquired bacterial skin and softtissue infections in children: An intersociety co nsensus on impetigo, abscess, and cellulitis treatment // Clin Ther. 2019. Vol. 41, N 3. P. 532–551.e17. doi: 10.1016/j.clinthera.2019.01.010

[11] Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol. 2017;(39):106–112. doi: 10.1016/j.mib.2017.10.028

[12] Theuretzbacher U. Global antimicrobial resistance in Gram-negative pathogens and clinical need // Curr Opin Microbiol. 2017. N 39. P. 106–112. doi: 10.1016/j.mib.2017.10.028

[13] Zhou YP, Wilder-Smith A, Hsu LY. The Role of international travel in the spread of methicillin-resistant Staphylococcus aureus. J Travel Med. 2014;21(4):272–281. doi: 10.1111/jtm.12133

[14] Zhou Y.P., Wilder-Smith A., Hsu L.Y. The Role of international travel in the spread of methicillin-resistant Staphylococcus aureus // J Travel Med. 2014. Vol. 21, N 4. P. 272–281. doi: 10.1111/jtm.12133

[15] Zabielinski M, McLeod MP, Aber C, et al. Trends and antibiotic susceptibility patterns of methicillin-resistant and methicillin-sensitive Staphylococcus aureus in an outpatient dermatology facility. JAMA Dermatol. 2013;149(4):427–432. doi: 10.1001/jamadermatol.2013.2424

[16] Zabielinski M., McLeod M.P., Aber C., et al. Trends and antibiotic susceptibility patterns of methicillin-resistant and methicillin-sensitive Staphylococcus aureus in an outpatient dermatology facility // JAMA Dermatol. 2013. Vol. 149, N 4. P. 427–432. doi: 10.1001/jamadermatol.2013.2424

[17] Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850–859. doi: 10.1101/gr.131029.111

[18] Kong H.H., Oh J., Deming C., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis // Genome Res. 2012. Vol. 22, N 5. P. 850–859. doi: 10.1101/gr.131029.111

[19] Baurecht H, Rühlemann MC, Rodríguez E, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018;141(5):1668–1676, 1676.e1–1676.e16. doi: 10.1016/j.jaci.2018.01.019

[20] Baurecht H., Rühlemann M.C., Rodríguez E., et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration // J Allergy Clin Immunol. 2018. Vol. 141, N 5. P. 1668–1676, 1676.e1–1676.e16. doi: 10.1016/j.jaci.2018.01.019

[21] Gonzalez T, Myers JM, Herr AB, Hershey KK. Staphylococcal biofilms in atopic dermatitis. Curr Allergy Asthma Rep. 2017;17(12):81. doi: 10.1007/s11882-017-0750-x

[22] Gonzalez T., Myers J.M., Herr A.B., Hershey K.K. Staphylococcal biofilms in atopic dermatitis // Curr Allergy Asthma Rep. 2017. Vol. 17, N 12. P. 81. doi: 10.1007/s11882-017-0750-x

[23] Shelton CL, Conrady DG, Herr AB. Functional consequences of B-repeat sequence variation in the staphylococcal biofilm protein Aap: Deciphering the assembly code. Biochem J. 2017;474(3):427–443. doi: 10.1042/BCJ20160675

[24] Shelton C.L., Conrady D.G., Herr A.B. Functional consequences of B-repeat sequence variation in the staphylococcal biofilm protein Aap: Deciphering the assembly code // Biochem J. 2017. Vol. 474, N 3. Р. 427–443. doi: 10.1042/BCJ20160675

[25] Ilyina TS, Romanova YM. Bacterial biofilms: Their role in chronical infection processes and the means to combat them. Mol Genet Microbiol Virol. 2021;39(2):14–24. (In Russ). doi: 10.17116/molgen20213902114

[26] Ильина Т.С., Романова Ю.М. Бактериальные биопленки: роль в хронических инфекционных процессах и поиск средств борьбы с ними // Молекулярная генетика, микробиология и вирусология. 2021. Т. 39, № 2. С. 14–24. doi: 10.17116/molgen20213902114

[27] Abdolrasouli A, Armstrong-James D, Ryan L, et al. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017;60(11):758–763. doi: 10.1111/myc.12699

[28] Abdolrasouli A., Armstrong-James D., Ryan L., et al. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris // Mycoses. 2017. Vol. 60, N 11. P. 758–763. doi: 10.1111/myc.12699

[29] Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: A review of the literature. Clin Microbiol Rev. 2018;31(1):e00029–17. doi: 10.1128/CMR.00029-17

[30] Jeffery-Smith A., Taori S.K., Schelenz S., et al. Candida auris: A review of the literature // Clin Microbiol Rev. 2018. Vol. 31, N 1. P. e00029–17. doi: 10.1128/CMR.00029-17

[31] Daneman N, Sarwar S, Fowler RA, et al. Effect of selective decontamination on antimicrobial resistance in intensive care units: A systematic review and meta-analysis. Lancet Infect Dis. 2013;13(4):328–341. doi: 10.1016/S1473-3099(12)70322-5

[32] Daneman N., Sarwar S., Fowler R.A., et al. Effect of selective decontamination on antimicrobial resistance in intensive care units: A systematic review and meta-analysis // Lancet Infect Dis. 2013. Vol. 13, N 4. P. 328–341. doi: 10.1016/S1473-3099(12)70322-5

[33] Huang H, Chen B, Wang HY, et al. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units. Korean J Intern Med. 2016;31(6):1159–1170. doi: 10.3904/kjim.2015.240

[34] Huang H., Chen B., Wang H.Y., et al. The efficacy of daily chlorhexidine bathing for preventing healthcare-associated infections in adult intensive care units // Korean J Intern Med. 2016. Vol. 31, N 6. P. 1159–1170. doi: 10.3904/kjim.2015.240

[35] Kaladze NN, Sukhareva IA, Yushchenko AY. Yu.S. Kryvoshein (On the 80th birthday of birthday). Crim J Exp Clin Med. 2019;9(3):83–87. (In Russ).

[36] Каладзе Н.Н., Сухарева И.А., Ющенко А.Ю. Ю.С. Кривошеин. К 80-летию со дня рождения // Крымский журнал экспериментальной и клинической медицины. 2019. Т. 9, № 3. С. 83–87.

[37] Wessels S, Ingmer H. Modes of action of three disinfectant active substances: A review. Regul Toxicol Pharmacol. 2013;67(3):456–467. doi: 10.1016/j.yrtph.2013.09.006

[38] Wessels S., Ingmer H. Modes of action of three disinfectant active substances: A review // Regul Toxicol Pharmacol. 2013. Vol. 67, N 3. P. 456–467. doi: 10.1016/j.yrtph.2013.09.006

[39] Ceragioli M, Mols M, Moezelaar R et al. Comparative transcriptomic and phenotypic analysis of the responses of Bacillus cereus to various disinfectant treatments. Appl Environ Microbiol. 2010;76(10):3352–3360. doi: 10.1128/AEM.03003-09

[40] Ceragioli M., Mols M., Moezelaar R., et al. Comparative transcriptomic and phenotypic analysis of the responses of Bacillus cereus to various disinfectant treatments // Appl Environ Microbiol. 2010. Vol. 76, N 10. P. 3352–3360. doi: 10.1128/AEM.03003-09

[41] Frolova AV, Kosinets AN. Comparative evaluation of the antimicrobial activity of traditional antiseptics and the herbal remedy “phytomp” against pathogens of surgical infection. Vitebsk State Med University; 2008. (In Russ).

[42] Фролова А.В., Косинец А.Н. Сравнительная оценка антимикробной активности традиционных антисептиков и растительного средства Фитомп в отношении возбудителей хирургической инфекции. Витебский государственный медицинский университет, 2008.

[43] Osmanov A, Wise A, Denning DW. In vitro and in vivo efficacy of miramistin against drug-resistant fungi. J Med Microbiol. 2019;68(7):1047–1052. doi: 10.1099/jmm.0.001007

[44] Osmanov A., Wise A., Denning D.W. In vitro and in vivo efficacy of miramistin against drug-resistant fungi // J Med Microbiol. 2019. Vol. 68, N 7. P. 1047–1052. doi: 10.1099/jmm.0.001007

[45] Krivorutchenko YL. Sensitivity to miramistin, amphotericin B and tauroside Sx1 fungi isolated from patients in the Crimea. Biomed Biosoc Anthropol. 2010. Р. 144–149. (In Russ).

[46] Криворутченко Ю.Л. Чувствительность к мирамистину, амфотерицину В и таурозиду Sx1 грибов, выделенных от больных в Крыму // Biomed Biosoc Anthropol. 2010. С. 144–149.

[47] Miramistin: collection of works. Ed. by Yu.S. Krivosheina. Moscow: Medical News Agency; 2004. 625 р. (In Russ).

[48] Мирамистин: сборник трудов / под ред. Ю.С. Кривошеина. Москва: Медицинское информационное агентство; 2004. 625 с.

RIGHTS & PERMISSIONS

Eco-Vector